UB
SMMT icon

UMB Bank’s Summit Therapeutics SMMT Stock Holding History

UMB Bank’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233 Sell
16
-8
-33% -$142 ﹤0.01% 2296
2026
Q1 		$455 Buy
+24
New +$388 ﹤0.01% 2261

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UMB Bank's SMMT Position: Q2 2026 in Review

UMB Bank reduced its Summit Therapeutics (SMMT) stake by 33% in Q2 2026, selling an estimated $142 and leaving 16 shares worth $233. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

UMB Bank first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $455 in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • UMB Bank held 16 shares of Summit Therapeutics worth $233 as of Q2 2026.
  • UMB Bank sold 8 Summit Therapeutics shares in Q2 2026, an estimated $142.
  • Summit Therapeutics made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #2296 holding.
  • UMB Bank first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • UMB Bank's Summit Therapeutics position peaked at $455 in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.